← All trials
NCT02021006
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2013
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 436
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BolognaLead sponsor
- IL Sogno di StefanoCollaborator
- Baskent UniversityOverall official - principal investigator
- Medical University of GdanskOverall official - principal investigator
- University of AnkaraOverall official - principal investigator
- University of MilanOverall official - principal investigator
- University of BolognaReponsible party - principal investigator
- Government of ItalyCollaborator
- University of BolognaOverall official - principal investigator
- University of BolognaStudy chair
- University of GenoaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.